Details for Patent: 9,040,074
✉ Email this page to a colleague
Which drugs does patent 9,040,074 protect, and when does it expire?
Patent 9,040,074 protects ZUSDURI and JELMYTO and is included in two NDAs.
This patent has nine patent family members in six countries.
Summary for Patent: 9,040,074
| Title: | Material and method for treating internal cavities |
| Abstract: | A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body. |
| Inventor(s): | Asher Holzer, Dorit Daniel, Michael MULLERAD, Jaime De La Zerda, Uri SHPOLANSKY, Nadav MALCHI, Yosh DOLLBERG, Dor TAL, Yossi YAVIN, Marina KONORTY |
| Assignee: | Urogen Pharma Ltd |
| Application Number: | US13/553,198 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,040,074 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 9,040,074
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urogen Pharma | ZUSDURI | mitomycin | POWDER;INTRAVESICAL | 215793-001 | Jun 12, 2025 | RX | Yes | Yes | 9,040,074 | ⤷ Start Trial | Y | TREATMENT OF ADULT PATIENTS WITH RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER | ⤷ Start Trial | |||
| Urogen Pharma | JELMYTO | mitomycin | POWDER;PYELOCALYCEAL | 211728-001 | Apr 15, 2020 | RX | Yes | Yes | 9,040,074 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,040,074
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Germany | 212011100034 | ⤷ Start Trial | |||
| Denmark | 2525777 | ⤷ Start Trial | |||
| European Patent Office | 2525777 | ⤷ Start Trial | |||
| European Patent Office | 2734187 | ⤷ Start Trial | |||
| Spain | 2732150 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
